Platelet inhibitors

PreclinicalSmall molecule

NNational Institute of Cardiology, Warsaw, Poland

Platelet inhibitors is one of 14 small molecule programs targeting Cardiovascular. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CardiovascularTerminated

CardiovascularPreclinical

Terminated

Competition

Competitive Landscape

17 competitors in Cardiovascular

#DrugCompanyPhaseTrials

Crestor

AstraZeneca

Approved

5 2

Ozempic

Novo Nordisk

Approved

3 3

Bayer Aspirin

Bayer

Approved

2 4

Cialis

Eli Lilly

Phase 3

1 5

Letairis

Gilead

Phase 3

1 6

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

3 7

Metformin XR

AstraZeneca

Phase 3

1 8

Xarelto

WWim Janssens

Phase 1

1 9

Dapansutrile

OOlatec Therapeutics LLC

Phase 1

1 10

Statins

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cardiovascular1 trial

Cardiovascular Magnetic Resonance for the Occluded Infarct-Related Artery Treatment

Terminated·NNational Institute of Cardiology, Warsaw, Poland·N/A·NCT00968383·11 enrolled

Trial1 trial

Occluded Artery Trial (OAT)

Completed·NNYU Langone Health·Phase 3·NCT00004562·2,201 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Platelet inhibitors. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Platelet inhibitors compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Platelet inhibitors. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Cardiology, Warsaw, Poland company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNational Institute of Cardiology, Warsaw, Poland

Platelet inhibitors

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cardiovascular1 trial

Trial1 trial

References

Drug Info

Quick Facts

Related News